By Michele Maatouk
Date: Tuesday 22 Aug 2017
LONDON (ShareCast) - (ShareCast News) - Sareum Holdings said on Tuesday that it expects full-year profit and cash at bank to be ahead of market expectations.
The AIM-listed specialist cancer drug discovery and development business will provide an update on progress with its cancer and autoimmune disease research and development programmes in mid-late October 2017, which is when it expects to report its full year results.
At 1000 BST, the shares were up 10.5% to 0.83p.
Email this article to a friend
or share it with one of these popular networks:
Currency | UK Pounds |
Share Price | 45.67p |
Change Today | 0.47p |
% Change | 1.03 % |
52 Week High | 135.00 |
52 Week Low | 10.25 |
Volume | 271,599 |
Shares Issued | 106.84m |
Market Cap | £48.79m |
RiskGrade | 594 |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
Strong Buy | 1 |
Buy | 0 |
Neutral | 0 |
Sell | 0 |
Strong Sell | 0 |
Total | 1 |
No dividends found |
Time | Volume / Share Price |
11:13 | 100 @ 45.20p |
10:49 | 25,000 @ 45.81p |
09:44 | 29,268 @ 46.11p |
10:42 | 5,000 @ 45.80p |
10:42 | 1,125 @ 47.00p |
You are here: research